MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Bevacizumab (Avastatin)

Nintedanib is active in malignant pleural mesothelioma cell models and inhibits angiogenesis and tumor growth in vivo

Clinical cancer research 2018 May 3 [Link] Laszlo V, Valko Z, Kovacs I, Ozsvar J, Hoda MA, Klikovits T, Lakatos D, Czirók A, Garay T, Stiglbauer A, Helbich TH, Groger M, Tovari J, Klepetko W, Pirker C, Grusch M, Berger W, Hilberg F, Hegedus B, Dome B Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is an […]

Comments Off on Nintedanib is active in malignant pleural mesothelioma cell models and inhibits angiogenesis and tumor growth in vivo

Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis

Cancer Medicine 2018 February 26 [Epub ahead of print] [Link] Chouaid C, Assié JB, Andujar P, Blein C, Tournier C, Vainchtock A, Scherpereel A, Monnet I, Pairon JC Abstract This study was undertaken to determine the healthcare burden of malignant pleural mesothelioma (MPM) in France and to analyze its associations with socioeconomic deprivation, population density, […]

Comments Off on Determinants of malignant pleural mesothelioma survival and burden of disease in France: a national cohort analysis

Anti-tumor immunotherapy in malignant pleural mesothelioma

Rev Mal Respir 2018 February 4 [Epub ahead of print] [Link] Scherpereel A, Willemin MC, Wasielewski E, Dhalluin X Abstract INTRODUCTION: Malignant pleural mesothelioma (MPM) is a quite rare cancer, but with increasing incidence, that is usually induced by previous asbestos exposure. Its prognosis is poor and there is no validated curative therapy to date. […]

Comments Off on Anti-tumor immunotherapy in malignant pleural mesothelioma

A review of bevacizumab in the treatment of malignant pleural mesothelioma

Future Oncology 2017 September [Epub ahead of print] [Link] Brosseau S, Assoun S, Naltet C, Steinmetz C, Gounant V, Zalcman G Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of patients. VEGF plays a key mitogen for MPM cells physiopathology. Bevacizumab, […]

Comments Off on A review of bevacizumab in the treatment of malignant pleural mesothelioma

The Effect of Aquaporin 1-Inhibition on Vasculogenic Mimicry in Malignant Mesothelioma

International Journal of Molecular Services 2017 November [Link] Pulford E, McEvoy J, Hocking A, Prabhakaran S, Griggs K, Klebe S Abstract Malignant mesothelioma (MM) is an aggressive malignancy of the serosal membranes, with poor overall survival and quality of life. Limited targeted treatment strategies exist due to restricted knowledge of pathogenic pathways. Vasculogenic mimicry (VM) […]

Comments Off on The Effect of Aquaporin 1-Inhibition on Vasculogenic Mimicry in Malignant Mesothelioma

Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial

Lung Cancer 2017 August [Epub 2017 May 12] [Link] Zhan M, Zheng H, Xu T, Yang Y, Li Q Abstract PURPOSE: Malignant pleural mesothelioma (MPM) is a rare malignancy, and pemetrexed/cisplatin (PC) is the gold standard first-line regime. This study evaluated the cost-effectiveness of the addition of bevacizumab to PC (with maintenance bevacizumab) for unresectable […]

Comments Off on Cost-effectiveness analysis of additional bevacizumab to pemetrexed plus cisplatin for malignant pleural mesothelioma based on the MAPS trial

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

Expert Opinion of Investigational Drugs 2017 July 6 [Epub ahead of print] [Link] Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, Mutti L Abstract INTRODUCTION: Malignant mesothelioma is a rare and lethal malignancy primarily affecting the pleura and peritoneum. Mesothelioma incidence is expected to increase worldwide and current treatments remain ineffective, leading to […]

Comments Off on Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date

Onco Targets and Therapy 2017 April [Link] Levin PA, Dowell JE Abstract Malignant pleural mesothelioma (MPM) is a rare, but aggressive cancer. Surgery and radiation offer limited benefit, and systemic chemotherapy remains the primary treatment modality for the majority of patients. Vascular endothelial growth factor (VEGF) and its receptor have been recognized as important players […]

Comments Off on Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date

Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma

Expert Review of Anticancer Therapy 2016 October 4 [Epub ahead of print] [Link] Chia PL, Russell P, Scott AM, John T Abstract INTRODUCTION: Malignant mesothelioma (MM) is an aggressive malignancy of the pleura and other serosal membranes originating from mesothelial cells that, despite decades of research, continues to have limited therapeutic options and is associated […]

Comments Off on Targeting the vasculature: anti-angiogenic agents for malignant mesothelioma

NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016

Journal of the National Comprehensive Cancer Network 2016 July 14 [Link] Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D’Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins […]

Comments Off on NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016